Navigation Links
Questcor to Conduct Conference Call to Discuss Reimbursement Process
Date:9/19/2012

ANAHEIM, Calif., Sept. 19, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will conduct a conference call to discuss the reimbursement process for H.P. Acthar Gel (repository corticotrophin injection) prescriptions. The call will take place on Thursday, September 20, 2012 at 11 a.m. ET, 8 a.m. PT.  The call can be accessed in the following ways:

  • By webcast: At Questcor's investor relations website: http://ir.questcor.com/.
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-941-9205. For participants outside the U.S., the dial-in number is 480-629-9771.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call. The dial-in number for U.S. participants is 800-406-7325. For participants outside the U.S., the replay dial-in number is 303-590-3030. The replay access code for all callers is 4566307#.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor has also launched a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Comments on Insurance Policy Bulletin
2. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
3. Questcor Pharmaceuticals to Present at Investor Conferences in September
4. Questcor Reports Second Quarter Financial Results
5. Questcor to Report Second Quarter Results on July 24, 2012
6. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
7. IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
8. Leading Researchers Outline Principles for Conduct of Comparative Effectiveness Research
9. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
10. Delcath To Conduct Second Quarter 2012 Results Conference Call
11. Sihuans First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Physician General Dr. ... and Alcohol Programs Jennifer Smith commended South ... training for and using naloxone, a life-saving overdose reversal ... , a recovery specialist and overdose survivor who was ... providers. "A significant part of fighting the ...
(Date:2/24/2017)... , Feb. 23, 2017 The U.S. ... the PhenoTest BC Kit, performed on the Pheno ... organisms that cause bloodstream infections and provide information ... respond to (antibiotic sensitivity). The test also reduces ... this important information, which can guide antibiotic treatment ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... It’s no ... which often leads to a host of health issues, including urinary incontinence. However, ... Society discovered that good overall muscle strength in older women, particularly in ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... for Shamanic Healing and Spiritual Awakening, is happy to announce her “Spring ... mind and body, these individual customized retreats offer the winter-weary soul an excellent ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Elisa Guajardo Carothers is not your typical ... to studying to become a nun. Now, she writes about God, when she isn’t swimming ... Know BC and AD, Here is BS! (Before Satan),” she offers a comedic look at ...
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate smart media center that ... songs, movies, TV shows and much more apps for user exploration. Its innovative acoustic ... view of 1280 x 720 provides crisp images with remarkable clarity and color. The ...
(Date:2/27/2017)... ... 2017 , ... Sunshine Coast Health Centre (SCHC), one of ... https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered massage ... commitment to innovation in drug rehab and alcohol treatment strategies beyond a "punishment" ...
Breaking Medicine News(10 mins):